|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Table S2. Associations of week 16 JIA-ACR response with baseline biomarker levels** | | | | | |
| **Biomarker, baseline \*** |  | **Week 16 clinical response, fold (R/NR) †** | | | |
|  | **JIA ACR30** | **JIA ACR50** | **JIA ACR70** | **JIA ACR90** |
| C-reactive protein |  | **-4.29** | **-6.98** | **-4.79** | **-3.65** |
| Interleukin-6 |  | -1.84 | **-3.40** | **-2.82** | **-2.19** |
| Serum amyloid A |  | -2.32 | **-4.91** | **-3.67** | -2.13 |
| Fibroblast Growth Factor, basic |  | -1.40 | **-1.68** | **-1.68** | -1.49 |
| Interleukin-8 |  | **-1.43** | **-1.67** | **-1.60** | -1.25 |
| Interferon-induced protein-10 |  | -1.16 | **-1.70** | **-1.49** | **-1.75** |
| Vascular Endothelial Growth Factor |  | -1.27 | **-1.51** | **-1.49** | -1.21 |
| Erythrocyte sedimentation rate (mm/h) |  | -1.14 | **-1.44** | **-1.44** | **-1.47** |
| Blood Neutrophils (density) |  | -1.20 | **-1.29** | **-1.24** | -1.04 |
| Blood Leukocytes (density) |  | -1.12 | **-1.17** | **-1.13** | -1.01 |
| \* Baseline levels of indicated serum analyte or hematology parameter reported for those with p<0.05 for responder (R) vs. nonresponder (NR) for at least one of the week 16 Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) response variables. Significance between response groups for baseline serum biomarker levels was assessed by General Linear Model analyses, with models adjusted for age, JIA disease subtype, and prior TNF-inhibitor use.  † Fold for geometric mean of responders over geometric mean of non-responders, for baseline levels of indicated biomarkers, reported for indicated week 16 JIA ACR response variable; values bolded and shaded when p<0.05.  JIA ACR30/50/70/90, ≥30/50/70/90% improvement in the American College of Rheumatology juvenile idiopathic arthritis response criteria | | | | | |